Young Kwang Chae

  • 2348 Citations

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research Interests

Personalized Cancer Therapy, Precision Medicine, Early Phase Clinical Trials, First-in-Human Study, Novel Combination Cancer Therapy, Targeted therapy, Immunotherapy, Biomarker Study, Novel Drug Development, Novel Drug Delivery System, Adaptive Clinical Trials Design, Cell Signaling Pathway, Immune Checkpoint Pathway

Training Experience

2011Residency, Albert Einstein Medical Center
2014Fellowship, University of Texas/MD Anderson Cancer Center

Education/Academic qualification

MBA, Johns Hopkins University

… → 2007

MPH, Johns Hopkins University

… → 2007

MD, Seoul National University

… → 2002

Research interests

  • Oncology

Fingerprint Dive into the research topics where Young Kwang Chae is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 7 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.


Research Output

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

Patel, S. P., Othus, M., Chae, Y. K., Giles, F. J., Hansel, D. E., Singh, P. P., Fontaine, A., Shah, M. H., Kasi, A., Baghdadi, T. A., Matrana, M., Gatalica, Z., Korn, W. M., Hayward, J., McLeod, C., Chen, H. X., Sharon, E., Mayerson, E., Ryan, C. W., Plets, M. & 2 others, Blanke, C. D. & Kurzrock, R., May 15 2020, In : Clinical Cancer Research. 26, 10, p. 2290-2296 7 p.

Research output: Contribution to journalArticle

Open Access
  • 4 Scopus citations

    Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer

    Park, W., Mezquita, L., Okabe, N., Chae, Y. K., Kwon, D., Saravia, D., Auclin, E., Planchard, D., Caramella, C., Ferrara, R., Agte, S., Oh, M., Mudad, R., Jahanzeb, M., Suzuki, H., Besse, B. & Lopes, G., Feb 4 2020, In : British Journal of Cancer. 122, 3, p. 340-347 8 p.

    Research output: Contribution to journalArticle

  • 2 Scopus citations

    Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

    trial investigators, Feb 2020, In : The Lancet Oncology. 21, 2, p. 271-282 12 p.

    Research output: Contribution to journalArticle

  • 24 Scopus citations

    Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

    Drilon, A., Siena, S., Dziadziuszko, R., Barlesi, F., Krebs, M. G., Shaw, A. T., de Braud, F., Rolfo, C., Ahn, M. J., Wolf, J., Seto, T., Cho, B. C., Patel, M. R., Chiu, C. H., John, T., Goto, K., Karapetis, C. S., Arkenau, H. T., Kim, S. W., Ohe, Y. & 16 others, Li, Y. C., Chae, Y. K., Chung, C. H., Otterson, G. A., Murakami, H., Lin, C. C., Tan, D. S. W., Prenen, H., Riehl, T., Chow-Maneval, E., Simmons, B., Cui, N., Johnson, A., Eng, S., Wilson, T. R. & Doebele, R. C., Feb 2020, In : The Lancet Oncology. 21, 2, p. 261-270 10 p.

    Research output: Contribution to journalArticle

  • 9 Scopus citations